Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03190473 · ClinicalTrials.gov registry record · NA
OPTIMIZE IDE for the Treatment of ACS
A NA study, sponsored by Svelte Medical Systems.
- Terminated
- Registry status
- NA
- Development phase
- 1,630
- Enrollment target
NCT03190473 is a NA study that was terminated before completion, run by Svelte Medical Systems. The registered enrollment target is 1,630 participants.
The verdict
NCT03190473, a NA study, was terminated before completion, sponsored by Svelte Medical Systems.
- TERMINATED
- Registry status
- NA
- Development phase
- 1,630 participants
- Enrollment target
Study Summary
Indication for use: "The Svelte DES is indicated for improving coronary luminal diameter in patients with symptomatic heart disease, including patients with non-ST elevation MI due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length with a reference vessel diameter of 2.25 mm - 4.00 mm
Interventions
- DEVICE DES
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,630 participants |
| Start Date | 2018-01-02 |
| Est. Completion | 2023-03-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03190473
The ClinicalTrials.gov registry entry for NCT03190473 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1,630 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Svelte Medical Systems, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DES is the first listed.
NCT03190473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03190473 about?
NCT03190473 is a clinical study titled "OPTIMIZE IDE for the Treatment of ACS". Indication for use: "The Svelte DES is indicated for improving coronary luminal diameter in patients with symptomatic heart disease, including patients with non-ST elevation MI due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent len...
What is the current status of trial NCT03190473?
This trial is currently terminated. It is a NA study. The enrollment target is 1,630 participants. The study started on 2018-01-02. Estimated completion is 2023-03-08.
What interventions are being tested in trial NCT03190473?
The interventions under investigation include: DES (DEVICE).
Who is sponsoring clinical trial NCT03190473?
This trial is sponsored by Svelte Medical Systems, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.